Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Using Laboratory Test Results for Surveillance During a New Outbreak of Acute Hepatitis in 3-Week- to 5-Year-Old Children in the United Kingdom, the Netherlands, Ireland, and Curaçao: Observational Cohort Study.
Swets MC, Kerr SR, MacKenna B, Fisher L, van Wijnen M, Brandwagt D, Schenk PW, Fraaij P, Visser LG, Bacon S, Mehrkar A, Nichol A, Twomey P, Matthews PC; ISARIC4C Hepatitis Study Group; Semple MG, Groeneveld GH, Goldacre B, Jones I, Baillie JK. Swets MC, et al. Among authors: visser lg. JMIR Public Health Surveill. 2024 Dec 23;10:e55376. doi: 10.2196/55376. JMIR Public Health Surveill. 2024. PMID: 39864403 Free PMC article.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: visser lg. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
Assessing West Nile virus (WNV) and Usutu virus (USUV) exposure in bird ringers in the Netherlands: a high-risk group for WNV and USUV infection?
de Bellegarde de Saint Lary C, Kasbergen LMR, Bruijning-Verhagen PCJL, van der Jeugd H, Chandler F, Hogema BM, Zaaijer HL, van der Klis FRM, Barzon L, de Bruin E, Ten Bosch Q, Koopmans MPG, Sikkema RS, Visser LG. de Bellegarde de Saint Lary C, et al. Among authors: visser lg. One Health. 2023 Apr 7;16:100533. doi: 10.1016/j.onehlt.2023.100533. eCollection 2023 Jun. One Health. 2023. PMID: 37363259 Free PMC article.
Coagulation and inflammatory response after intramuscular or intradermal mRNA-1273 SARS-CoV-2 vaccine: secondary analysis of a randomized trial.
van Dijk WJ, Prins MLM, Roukens AHE, Roozen GVT, Roestenberg M, Visser LG, van Hylckama Vlieg A, Rosendaal FR. van Dijk WJ, et al. Among authors: visser lg. Res Pract Thromb Haemost. 2024 Apr 24;8(3):102419. doi: 10.1016/j.rpth.2024.102419. eCollection 2024 Mar. Res Pract Thromb Haemost. 2024. PMID: 38779329 Free PMC article.
Longitudinal soluble marker profiles reveal strong association between cytokine storms resulting from macrophage activation and disease severity in COVID-19 disease.
van Meijgaarden KE, van Veen S, Tsonaka R, Ruibal P, Roukens AHE, Arbous SM, Manniën J, Cannegieter SC, Ottenhoff THM, Joosten SA; BEAT-COVID group; COVID-19 LUMC group. van Meijgaarden KE, et al. Sci Rep. 2024 Jun 5;14(1):12882. doi: 10.1038/s41598-024-63586-8. Sci Rep. 2024. PMID: 38839796 Free PMC article.
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT, Prins MLM, Prins C, Janse JJ, de Gruyter HLM, Pothast CR, Huisman W, Koopman JPR, Lamers OAC, Kuijer M, Myeni SK, van Binnendijk RS, Hartog GD, Heemskerk MHM, Jochems SP, Feltkamp MCW, Kikkert M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Roozen GVT, et al. Among authors: visser lg. Clin Microbiol Infect. 2024 Jul;30(7):930-936. doi: 10.1016/j.cmi.2024.03.028. Epub 2024 Mar 28. Clin Microbiol Infect. 2024. PMID: 38552793 Free article. Clinical Trial.
Protective efficacy of short-term infection with Necator americanus hookworm larvae in healthy volunteers in the Netherlands: a single-centre, placebo-controlled, randomised, controlled, phase 1 trial.
Hoogerwerf MA, Janse JJ, Kuiper VP, van Schuijlenburg R, Kruize YC, Sijtsma JC, Nosoh BA, Koopman JR, Verbeek-Menken PH, Westra IM, Meij P, Brienen EA, Visser LG, van Lieshout L, Jochems SP, Yazdanbakhsh M, Roestenberg M. Hoogerwerf MA, et al. Among authors: visser lg. Lancet Microbe. 2023 Dec;4(12):e1024-e1034. doi: 10.1016/S2666-5247(23)00218-5. Lancet Microbe. 2023. PMID: 38042152 Free article. Clinical Trial.
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Among authors: visser lg. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
239 results